Blackstone Has Explored Sale of ZO Skin Health
The private equity firm is considering a sale of the physician-dispensed skincare brand.
Updated on Sept. 19, 2026 in Beauty
Live Poll
Do you prefer buying skincare products through a dermatologist rather than traditional retail stores?
Blackstone is exploring a potential sale of ZO Skin Health, a move that could value the skincare brand at approximately $2 billion. The company, founded in 2007, has grown its market presence through a network of authorized physicians and dedicated revenue-sharing programs.
Why it matters
The potential sale highlights the continued growth of the medical-aesthetics industry, where brands prioritize physician partnerships to maintain product integrity. This distribution model has historically helped the company secure market-leading positions in regions like the European Union.
In 2025, the brand achieved a repeat purchase rate of nearly 40% among customers at medical-aesthetics practices. This figure reflects the company's reliance on a model where products are dispensed directly through professional channels.
The players
Blackstone
A global private equity firm that manages large-scale investments in healthcare and consumer brands.
ZO Skin Health
A developer of medical-grade skincare products designed to be distributed through licensed physicians.
Cutera
A medical technology company that develops energy-based aesthetic systems and previously distributed ZO products in Japan.
The details
The brand operates by restricting its product distribution to official online channels and authorized medical practices. By utilizing physician affiliate and revenue-sharing programs, the company incentivizes practitioners to incorporate these specific treatments into their patient care plans. This closed-loop system is designed to protect premium pricing and ensure the clinical integrity of the brand's offerings.
Timeline
2007: ZO Skin Health was founded.
2012: The company launched physician affiliate and revenue-sharing programs.
2016: ZO became the No. 1 physician-dispensed medical skincare brand in the European Union.
2020: Blackstone acquired a majority stake in ZO Skin Health.
2025: Customer repeat purchase rate reached nearly 40%.
Health Landscape
The potential sale reflects the ongoing financial consolidation occurring within the $17 billion global aesthetics industry. It signals a move toward scaling physician-dispensed brands as consumer demand for clinically backed skincare continues to outpace traditional retail options.
While a change in ownership may not alter product formulations, patients should continue to source these items directly through authorized medical providers to ensure product authenticity. If you use physician-dispensed lines, maintain regular check-ins with your dermatologist to ensure your regimen remains appropriate for your skin health needs.
The takeaway
The move underscores the value placed on physician-backed skincare lines in a competitive global market. Patients using such products should always prioritize ordering through verified clinical accounts to ensure they are receiving authentic, professional-grade items.
Further reading
For more on the current trends in clinical-grade products, visit Beauty.
Source note: This article includes information reported by Fortune.
Live Poll
Do you prefer buying skincare products through a dermatologist rather than traditional retail stores?
